Eton Pharma gets FDA approval for KHINDIVI oral solution; peak sales >$50M

Eton Pharmaceuticals, Inc.

KHINDIVI is the first and only FDA-approved hydrocortisone oral solution for pediatric adrenocortical insufficiency.
Commercial launch expected week of June 2, 2025; product distributed through Anovo specialty pharmacy.
Combined peak sales of KHINDIVI and ALKINDI SPRINKLE expected to exceed $50 million per year.
Indicated for patients 5 years and older; eliminates need to split or crush tablets for accurate dosing.
Eton's rare disease sales team to promote alongside ALKINDI SPRINKLE; Eton Cares program offers $0 co-pay for qualifying patients.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.